What is an Accelerated Share Repurchase Agreement (ASR)?

An Accelerated Share Repurchase Agreement is a contract where a company buys back a significant amount of its own stock from an investment bank. This allows the company to repurchase its shares quickly and efficiently, often at a predetermined price or discount.

Why would Edwards Lifesciences enter into an ASR at this time?

Companies typically enter into ASRs when they believe their stock is undervalued, wish to return capital to shareholders, or manage their outstanding share count. It signals management's confidence in the company's future prospects and financial stability.

Where can I find more details about the ASR?

The 8-K filing indicates that a press release announcing the ASR was issued on November 1, 2022, and is included as Exhibit 99.1. Investors should refer to this press release for specific details regarding the amount of the repurchase, the number of shares involved, and the expected completion timeline.

How will this ASR affect Edwards Lifesciences' stock price?

Share repurchases, especially accelerated ones, can potentially increase a company's earnings per share (EPS) by reducing the number of outstanding shares. This can also signal positive sentiment, potentially supporting or increasing the stock price. However, the actual impact depends on the size of the repurchase relative to the company's market capitalization and overall market conditions.

EW 8-K SEC Disclosure — Nov 1, 2022

Summary

Edwards Lifesciences Corporation (EW) announced on November 1, 2022, its entry into an Accelerated Share Repurchase Agreement (ASR). This move signifies management's confidence in the company's stock and its commitment to returning capital to shareholders. While the specific details of the ASR agreement, such as the total dollar amount or the number of shares to be repurchased, are not fully detailed in this 8-K filing itself, the press release incorporated by reference likely provides these crucial figures. Investors should review the associated press release for a comprehensive understanding of the share repurchase program's scope and potential impact on the company's financials and stock valuation.

Key Highlights

1Edwards Lifesciences entered into an Accelerated Share Repurchase Agreement (ASR) on October 31, 2022.
2The ASR is a significant capital allocation decision by the company.
3This action suggests management's belief in the undervaluation of EW's stock.
4The company is actively returning capital to shareholders through share buybacks.
5Further details on the ASR terms are expected to be in the press release filed as an exhibit.

Edwards Lifesciences Corp 8-K Report, Corporate Update (Nov 1, 2022)

Summary

Key Highlights

Frequently Asked Questions